Kite receives FDA priority review for axicabtagene ciloleucel
Kite Pharma announced the FDA has accepted for priority review the Biologics License Application for axicabtagene ciloleucel. The submission follows positive data demonstrated with a single infusion of axicabtagene ciloleucel in the ZUMA-1 Phase 2 trial in patients with refractory aggressive NHL. May 26, 2017